Amir Guerami, MD
Ophthalmology · Encino, CANPI 1457475303
Payments from drug & device makers
Across 198 payments — averaging $2634.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$212K
- Regeneron$202K
- AstraZeneca$82K
- Genentech, Inc.$19K
- Genentech USA, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $2K from 17 others
Across 10 payments — averaging $292.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
What the payments were for
- Consulting fees$6,51649%
- Grants$1,2009%
- Food & beverage$5,50042%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 47 | $211,682 |
| Regeneron | 23 | $201,547 |
| AstraZeneca | 3 | $81,504 |
| Genentech, Inc. | 6 | $19,423 |
| Genentech USA, Inc. | 32 | $2,895 |
| Regeneron Healthcare Solutions, Inc. | 30 | $2,235 |
| AbbVie(2 entities) | 15 | $414 |
| Alimera Sciences, Inc. | 9 | $372 |
| Coherus Oncology, Inc. | 8 | $283 |
| Astellas Pharma US Inc | 4 | $219 |
| Novartis | 2 | $217 |
| Dutch Ophthalmic, USA | 2 | $167 |
| Alcon | 1 | $128 |
| Sight Sciences, Inc. | 1 | $121 |
| Sandoz | 4 | $94 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Biogen | 2 | $58 |
| Bausch & Lomb Americas Inc. | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Eyepoint US, Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$4,536
- Lucentis$2,364
- EYLEA$1,439
- EVA, combined machine$148
- TISSUEBLUE$148
- Iluvien$133
- Cimerli$132
- Constellation$128
- VABYSMO$125
- OMNI(R) SURGICAL SYSTEM (US)$121
- Izervay$115
- Non-Covered Product$111
How this compares
$521,565 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 24 | $7,646 |
| Prednisolone Acetate | 98 | $2,690 |
| Brimonidine Tartrate | 60 | $2,371 |
| Difluprednate | 22 | $1,880 |
| Latanoprost | 109 | $808 |
| Ketorolac Tromethamine | 36 | $720 |
| Atropine Sulfate | 34 | $655 |
| MoxifloxacinMoxifloxacin Hcl | 33 | $563 |
| Timolol Maleate | 57 | $441 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Encino
- Robert EngstromEncino$3.4M
- Hajir DadgostarEncino$1.5M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.